The Diabetic Retinopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Retinopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued products.
GlobalData tracks 161 drugs in development for Diabetic Retinopathy by 131 companies/universities/institutes. The top development phase for Diabetic Retinopathy is preclinical with 96 drugs in that stage. The Diabetic Retinopathy pipeline has 149 drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Diabetic Retinopathy pipeline products market are: Novaliq, F. Hoffmann-La Roche and PharmAbcine.
The key targets in the Diabetic Retinopathy pipeline products market include Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, and Placenta Growth Factor.
The key mechanisms of action in the Diabetic Retinopathy pipeline product include Vascular Endothelial Growth Factor A Inhibitor with 15 drugs in Pre-Registration. The Diabetic Retinopathy pipeline products include 14 routes of administration with the top ROA being Oral and 16 key molecule types in the Diabetic Retinopathy pipeline products market including Small Molecule, and Monoclonal Antibody.
Diabetic Retinopathy overview
Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings in the vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use.
For a complete picture of Diabetic Retinopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
